Drug factory · FDA FEI 3002785310

Matrix Pharmacorp Private Limited

Unit 8, Gaitula Chodavaram, Poosapatirega Mandal, Vizianagaram, India

India: 1

Problems found, fixed voluntarily at FDA's last inspection, Jul 17, 2026.

Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.

8 drug inspections on record since 2009: 4 with no problems, 3 with problems fixed voluntarily, 1 with FDA action.

What it does, for whom

DrugRoleForNDC
AbacavirMakes the active ingredient Cipla USA., Inc. 69097-514

FDA inspection history

EndedResultProgramProblems noted
Jul 17, 2026Problems found, fixed voluntarilyDrug Quality Assurance—
May 5, 2023No problems foundDrug Quality Assurance—
Jun 5, 2019Serious problems, FDA actionDrug Quality Assurance—
Dec 10, 2018Problems found, fixed voluntarilyDrug Quality Assurance—
Apr 13, 2018No problems foundDrug Quality Assurance—
Apr 17, 2015No problems foundDrug Quality Assurance—
Aug 2, 2012No problems foundDrug Quality Assurance—
Apr 10, 2009Problems found, fixed voluntarilyDrug Quality Assurance—

Registered with FDA for: analysis; api manufacture; manufacture; pack.